Evidence map›Paper›PMID 32665614›Full record

ArticleScientific reports2020

Liver nucleotide biosynthesis is linked to protection from vascular complications in individuals with long-term type 1 diabetes.

Ruchi Jain, Türküler Özgümüş, Troels Mygind Jensen, Elsa du Plessis, Magdalena Keindl, Cathrine Laustrup Møller, Henrik Falhammar, Thomas Nyström, Sergiu-Bogdan Catrina, Gun Jörneskog and 16 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 12 institutions in 6 countries.

Ruchi JainDepartment of Clinical Science/Diabetes and Endocrinology, Lund University Diabetes Centre, 205 02, Malmö, Sweden.
Türküler ÖzgümüşDepartment of Clinical Science, Center for Diabetes Research, University of Bergen, 5032, Bergen, Norway.
Troels Mygind JensenResearch Unit for General Practice, Danish Aging Research Center, University of Southern Denmark, Odense, Denmark.
Elsa du PlessisDepartment of Clinical Science, Center for Diabetes Research, University of Bergen, 5032, Bergen, Norway.
Magdalena KeindlDepartment of Clinical Science, Center for Diabetes Research, University of Bergen, 5032, Bergen, Norway.
Cathrine Laustrup MøllerSteno Diabetes Center Copenhagen, Gentofte, Denmark.
Henrik FalhammarDepartment of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
Thomas NyströmDepartment of Clinical Science and Education, Division of Internal Medicine, Unit for Diabetes Research, Karolinska Institute, South Hospital, Stockholm, Sweden.
Sergiu-Bogdan CatrinaDepartment of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
Gun JörneskogDepartment of Clinical Sciences, Division of Internal Medicine, Karolinska Institute, Danderyd University Hospital, Stockholm, Sweden.
Leon Eyrich JessenDepartment of Health Technology, Section for Bioinformatics, Technical University of Denmark, Lyngby, Denmark.
Carol ForsblomFolkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland.
Jani K HaukkaFolkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland.
Per-Henrik GroopFolkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland.
Peter RossingSteno Diabetes Center Copenhagen, Gentofte, Denmark.
Leif GroopDepartment of Clinical Science/Diabetes and Endocrinology, Lund University Diabetes Centre, 205 02, Malmö, Sweden.
Mats EliassonDepartment of Public Health and Clinical Medicine, Sunderby Research Unit, Umeå University, Umeå, Sweden.
Björn EliassonDepartment of Medicine, University of Gothenburg, Gothenburg, Sweden.
Kerstin BrismarDepartment of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden.
Mahmoud Al-MajdoubDepartment of Clinical Science/Diabetes and Endocrinology, Lund University Diabetes Centre, 205 02, Malmö, Sweden.
Peter M NilssonDepartment of Clinical Science/Diabetes and Endocrinology, Lund University Diabetes Centre, 205 02, Malmö, Sweden.
Marja-Riitta TaskinenResearch Program Unit, Clinical and Molecular Metabolism, University of Helsinki, Helsinki, Finland.
Ele FerranniniInstitute of Clinical Physiology, CNR, Pisa, Italy.
Peter SpégelCentre for Analysis and Synthesis, Department of Chemistry, Lund University, 223 62, Lund, Sweden.
Tore Julsrud BergInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Valeriya LyssenkoDepartment of Clinical Science/Diabetes and Endocrinology, Lund University Diabetes Centre, 205 02, Malmö, Sweden. valeriya.lyssenko@uib.no.
Karolinska Institutet · SELund University · SEUniversity of Bergen · NOUniversity of Helsinki · FISteno Diabetes Center · DKHelsinki University Hospital · FIIstituto di Fisiologia Clinica · ITOslo University Hospital · NOTechnical University of Denmark · DKUmeå University · SEUniversity of Gothenburg · SEUniversity of Southern Denmark · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Identification of biomarkers associated with protection from developing diabetic complications is a prerequisite for an effective prevention and treatment. The aim of the present study was to identify clinical and plasma metabolite markers associated with freedom from vascular complications in people with very long duration of type 1 diabetes (T1D). Individuals with T1D, who despite having longer than 30 years of diabetes duration never developed major macro- or microvascular complications (non-progressors; NP) were compared with those who developed vascular complications within 25 years from diabetes onset (rapid progressors; RP) in the Scandinavian PROLONG (n = 385) and DIALONG (n = 71) cohorts. The DIALONG study also included 75 healthy controls. Plasma metabolites were measured using gas and/or liquid chromatography coupled to mass spectrometry. Lower hepatic fatty liver indices were significant common feature characterized NPs in both studies. Higher insulin sensitivity and residual ß-cell function (C-peptide) were also associated with NPs in PROLONG. Protection from diabetic complications was associated with lower levels of the glycolytic metabolite pyruvate and APOCIII in PROLONG, and with lower levels of thiamine monophosphate and erythritol, a cofactor and intermediate product in the pentose phosphate pathway as well as higher phenylalanine, glycine and serine in DIALONG. Furthermore, T1D individuals showed elevated levels of picolinic acid as compared to the healthy individuals. The present findings suggest a potential beneficial shunting of glycolytic substrates towards the pentose phosphate and one carbon metabolism pathways to promote nucleotide biosynthesis in the liver. These processes might be linked to higher insulin sensitivity and lower liver fat content, and might represent a mechanism for protection from vascular complications in individuals with long-term T1D.

Indexed as

AgedBiomarkersBlood GlucoseC-PeptideDiabetes ComplicationsDiabetes Mellitus, Type 1FemaleGenetic Predisposition to DiseaseHumansInsulin ResistanceLiverMaleMetabolomicsMiddle AgedNucleotidesBiomarkersBlood GlucoseC-PeptideNucleotides

Identifiers

PMID32665614
PMCPMC7360755
OpenAlexW3042988176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.